24 / 74
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 6, November/December 2018
356
AFRICA
this study as the number of patients and follow-up duration
could not provide reliable information on these issues. Finally,
NT-proBNP levels were not used as inclusion criteria because
they are not part of Health Canada and United States Food and
Drug Administration recommendations.
Conclusions
This prospective evaluation demonstrated that our algorithm
for titration of sacubitril/valsartan, developed in a tertiary HF
clinic, is a safe and easy-to-use tool in daily practice. Using this
titration algorithm, we were able to reach the maximal dose
of sacubitril/valsartan in almost half of our patients, with a
tolerability profile in line with the original PARADIGM-HF
study.
We acknowledge Michelle Dubois, RN for her help in the preparation of the
manuscript and Serge Simard for his work on the biostatistics. Dr Bergeron,
Mrs Audrey Vachon, Mrs Julie Boisvert, Mr Sylvain Gilbert and Mr Vincent
Leclerc received consulting fees from Novartis.
References
1.
Ezekowitz J, Fedak P, Lepage S,
et al
. 2016 report on the health of
Canadians. The burden of heart failure In:
Heart and Stroke Foundation
.
2.
The SOLVD Investigators. Effect of enalapril on survival in patients
with reduced left ventricular ejection fractions and congestive heart
failure.
N Engl J Med
1991;
325
: 293–302.
3.
The CONSENSUS Trial Study Group. Effects of enalapril on mortal-
ity in severe congestive heart failure. Results of the Cooperative North
Scandinavian Enalapril Survival Study (CONSENSUS).
N Engl J Med
1987;
316
: 1429–1435.
4.
MERIT-HF study group. Effect of metoprolol CR/XL in chronic
heart failure: Metoprolol CR/XL Randomised Intervention Trial in
Congestive Heart Failure (MERIT-HF).
Lancet
1999;
353
: 2001–2007.
5.
CIBIS-II Investigators and Committees. The Cardiac Insufficiency
Bisoprolol Study II (CIBIS-II): a randomised trial.
Lancet
1999;
353
: 9–13.
6.
Pitt B, Zannad F, Remme WJ,
et al
. The effect of spironolactone
on morbidity and mortality in patients with severe heart failure.
Randomized Aldactone Evaluation Study Investigators.
N Engl J Med
1999;
341
: 709–717.
7.
Zannad F, McMurray JJ, Krum H,
et al.
Eplerenone in patients with
systolic heart failure and mild symptoms.
N Engl J Med
2011;
364
:
11–21.
8.
Cleland JG, Daubert JC, Erdmann E,
et al
. The effect of cardiac resyn-
chronization on morbidity and mortality in heart failure.
N Engl J Med
2005;
352
: 1539–1549.
9.
Moss AJ, Hall WJ, Cannom DS,
et al
. Cardiac-resynchronization
therapy for the prevention of heart-failure events.
N Engl J Med
2009;
361
: 1329–1338.
10. Tang AS, Wells GA, Talajic M,
et al
. Cardiac-resynchronization therapy
for mild-to-moderate heart failure.
N Engl J Med
2010;
363
: 2385–2395.
11. Bristow MR, Saxon LA, Boehmer J,
et al.
Cardiac-resynchronization
therapy with or without an implantable defibrillator in advanced chronic
heart failure.
N Engl J Med
2004;
350
: 2140–2150.
12. Bardy GH, Lee KL, Mark DB,
et al.
Amiodarone or an implantable
cardioverter-defibrillator for congestive heart failure.
N Engl J Med
2005;
352
: 225–237.
13. Moss AJ, Zareba W, Hall WJ,
et al
. Prophylactic implantation of a
defibrillator in patients with myocardial infarction and reduced ejection
fraction.
N Engl J Med
2002;
346
: 877–883.
14. McMurray JJ, Packer M, Desai AS,
et al
. Angiotensin-neprilysin inhibi-
tion versus enalapril in heart failure.
N Engl J Med
2014;
371
: 993–1004.
15. Howlett JG, Chan M, Ezekowitz JA,
et al
. The Canadian Cardiovascular
Society Heart Failure Companion: Bridging Guidelines to Your Practice.
Can J Cardiol
2016;
32
: 296–310.
16. Maggioni AP, Anker SD, Dahlstrom U,
et al
. Are hospitalized or ambu-
latory patients with heart failure treated in accordance with European
Society of Cardiology guidelines? Evidence from 12,440 patients of
the ESC Heart Failure Long-Term Registry.
Eur J Heart Fail
2013;
15
:
1173–1184.
17. Lenzen MJ, Boersma E, Reimer WJ,
et al
. Under-utilization of evidence-
based drug treatment in patients with heart failure is only partially
explained by dissimilarity to patients enrolled in landmark trials: a
report from the Euro Heart Survey on Heart Failure.
Eur Heart J
2005;
26
: 2706–2713.
18. Vardeny O, Claggett B, Packer M,
et al
. Efficacy of sacubitril/valsartan
vs. enalapril at lower than target doses in heart failure with reduced
ejection fraction: the PARADIGM-HF trial.
Eur J Heart Fail
2016;
18
:
1228–1234.
19. Senni M, McMurray JJ, Wachter R,
et al
. Initiating sacubitril/valsartan
(LCZ696) in heart failure: results of TITRATION, a double-blind,
randomized comparison of two uptitration regimens.
Eur J Heart Fail
2016;
18
: 1193–202.